Activist Commentary: Starboard is a very successful activist investor and has extensive experience helping companies focus on operational efficiency and margin improvement. Starboard has taken a ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has Johnson & Johnson’s consumer health spinout Kenvue in its sights.

The financial terms were not disclosed. LVMH’s cruise business consists of cruise retailer Starboard Cruise Services and Onboard Media, a multimedia solutions business for the global travel and ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer and wants the struggling drugmaker to make ...

He also shared a version of the presentation his hedge fund Starboard presented to Pfizer officials at a meeting last week. "It's not often that investors and shareholders are able to see what we ...

NEW YORK--(BUSINESS WIRE)--Starboard Value LP (together with its affiliates, “Starboard” or “we”), a significant shareholder of Pfizer Inc. (NYSE: PFE ...

Activist investor Starboard Value has amassed a $1 billion stake in Pfizer, according to a report, with a turnaround in its ...

Starboard Value LP is an investment adviser with a focused and differentiated fundamental approach to investing in publicly traded companies. Starboard invests in deeply undervalued companies and ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job. Starboard has called on Pfizer’s board to “hold management ...

Starboard Chief Executive Jeff Smith, whose fund has a roughly $1 billion stake in Pfizer, said Tuesday that the pharmaceutical company's board should be laser-focused on tracking its return on R ...

NEW YORK (Reuters) -Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold management accountable for its underperformance ...